Clinical Trial: Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units

Study Status: Completed
Recruit Status: Completed
Study Type: Observational

Official Title: Effects of Piperacillin-Tazobactam Use on the Prevalence Rate of Extended-Spectrum Beta-Lactamase (ESBL) Producing Escherichia Coli and Klebsiella Pneumoniae in Hematology

Brief Summary: To determine the value of increasing use of piperacillin/tazobactam as empiric therapy and restricting extended-spectrum cephalosporins in reducing the cases of ESBL producing Escherichia coli and Klebsiella pneumoniae in hematology and oncology units

Detailed Summary:
Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Current Primary Outcome:

Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Wyeth is now a wholly owned subsidiary of Pfizer

Dates:
Date Received: September 11, 2005
Date Started: February 2005
Date Completion:
Last Updated: March 14, 2007
Last Verified: March 2007